Primary open-angle glaucoma.
Primary open-angle glaucoma (POAG), by far the most common form of glaucoma, currently afflicts more than 2 million Americans, more than half of whom probably don't know they have it. Asymptomatic in the early stages, it gradually and progressively reduces the visual field and leads to blindness if untreated. Elevated intraocular pressure is believed to play a role, yet some people with normal pressure develop POAG. There is no single diagnostic test; screening and diagnosis involve periodic comprehensive eye evaluations. Treatment is aimed at delaying onset, slowing progression, and preserving vision.
Sharts-Hopko
Nancy C
NC
Villanova University College of Nursing, Pennsylvania, USA.
Glynn-Milley
Catherine
C
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D018679:Cholinergic Agonists / Q000627:therapeutic use; D018450:Disease Progression; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006293:Health Promotion; D006801:Humans; D053685:Laser Therapy; D008019:Life Style; D008403:Mass Screening; D009730:Nursing Assessment; D010353:Patient Education as Topic; D015995:Prevalence; D012307:Risk Factors; D014065:Tonometry, Ocular; D014130:Trabeculectomy; D014481:United States / Q000453:epidemiology
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D018679:Cholinergic Agonists